syrosingopine has been researched along with Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Q; Chen, W; Qin, L; Sun, J; Wang, G; Wang, Y | 1 |
| Guo, F; He, C; Qin, J; Wang, P; Wang, Y; Wu, S; Xu, L | 1 |
| Benjamin, D; Colombi, M; El-Shemerly, MY; Hall, MN; Hindupur, SK; Lane, HA; Maira, SM; Moroni, C; Pohlmann, J; Robay, D | 1 |
1 review(s) available for syrosingopine and Neoplasms
| Article | Year |
|---|---|
Novel strategies to improve tumour therapy by targeting the proteins MCT1, MCT4 and LAT1.
Topics: Antineoplastic Agents; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Large Neutral Amino Acid-Transporter 1; Molecular Structure; Monocarboxylic Acid Transporters; Muscle Proteins; Neoplasms; Symporters | 2021 |
2 other study(ies) available for syrosingopine and Neoplasms
| Article | Year |
|---|---|
Lactate Efflux Inhibition by Syrosingopine/LOD Co-Loaded Nanozyme for Synergetic Self-Replenishing Catalytic Cancer Therapy and Immune Microenvironment Remodeling.
Topics: Biological Transport; Humans; Lactic Acid; Neoplasms; Tumor Microenvironment | 2023 |
Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells.
Topics: Acids; Animals; Cell Line, Tumor; Energy Metabolism; Humans; Intracellular Space; Lactic Acid; Male; Metformin; Mice, Inbred C57BL; Monocarboxylic Acid Transporters; Muscle Proteins; NAD; Neoplasms; Reserpine; Symporters; Synthetic Lethal Mutations | 2018 |